Lupin receives USFDA approval to market a generic medication for swelling and pain in the eye, a generic equivalent of Sun Pharma's BromSite Ophthalmic Solution.
New Delhi, Feb 6 (PTI) Drug maker Lupin on Tuesday said it has received approval from the US health regulator to market a generic medication to treat swelling and pain in the eye.
The company has received approval from the US Food and Drug Administration (USFDA) for Bromfenac Ophthalmic Solution, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Sun Pharma's BromSite Ophthalmic Solution, it added.
Lupin is the exclusive first-to-file for this product, the drug maker said.
Shares of Lupin ended 0.43 per cent higher at Rs 1,579.75 apiece on the BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback